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Abstract: No data on antibiotic resistance in bloodstream infection (BSI) in people living with HIV
(PLWH) exist. The objective of this study was to describe BSI epidemiology in PLWH focusing
on multidrug resistant (MDR) organisms. A retrospective, single-center, observational study was
conducted including all positive blood isolates in PLWH from 2004 to 2017. Univariable and
multivariable GEE models using binomial distribution family were created to evaluate the association
between MDR and mortality risk. In total, 263 episodes (299 isolates) from 164 patients were analyzed;
126 (48%) BSI were community-acquired, 137 (52%) hospital-acquired. At diagnosis, 34.7% of the
patients had virological failure, median CD4 count was 207/µL. Thirty- and 90-day mortality rates
were 24.2% and 32.4%, respectively. Thirty- and 90-day mortality rates for MDR isolates were 33.3%
and 46.9%, respectively (p < 0.05). Enterobacteriaceae were the most prevalent microorganisms
(29.8%), followed by Coagulase-negative staphylococci (21.4%), and S. aureus (12.7%). In BSI due
to MDR organisms, carbapenem-resistant K. pneumoniae and methicillin-resistant S. aureus were
associated with mortality after adjustment for age, although this correlation was not confirmed after
further adjustment for CD4 < 200/µL. In conclusion, BSI in PLWH is still a major problem in the
combination antiretroviral treatment era and it is related to a poor viro-immunological status, posing
the question of whether it should be considered as an AIDS-defining event.
Keywords: bloodstream infections; HIV; multidrug resistant
1. Introduction
HIV infection has various effects on cellular and humoral immunity, such as defective cell-mediated
immunity and altered B-cell function. Furthermore, qualitative and quantitative neutrophil deficits
and skin and mucous membrane defects predispose persons living with HIV (PLWH) to develop
bacterial infections more frequently than a HIV-seronegative patient [1]. Infections in this population
Microorganisms 2020, 8, 1210; doi:10.3390/microorganisms8081210 www.mdpi.com/journal/microorganisms
Microorganisms 2020, 8, 1210 2 of 12
could be severe, leading not only to prolonged hospitalization and mortality but also to admittance in
an intensive care unit (ICU) [2,3].
Indeed, in the post combination antiretroviral treatment (cART) era, PLWH are more frequently
admitted to ICU due to blood stream infections (BSIs) than to Pneumocystis jiroveci pneumonia [4].
According to recent literature [5], clinical manifestations of BSIs in PLWH are similar to those in
HIV seronegative patients; however, BSI incidence and mortality are often higher in HIV population [6].
Nowadays, bacterial infections account for 15% of mortality causes among HIV patients in the United
States [7].
Concerning BSI epidemiology, differences have been described according to different geographical
distribution of pathogens and access to cART. Indeed, in industrialized countries, cART has determined
a reduction in incidence and a change of BSI clinical characteristics. In particular, reported predominant
pathogens are Non-typhoidal Salmonella, S. aureus, S. pneumoniae and Coagulase-negative staphylococci
(CoNS), with few data on antibiotic resistance profile [8].
Risk factors for BSIs in PLWH are high HIV-RNA, low CD4 cell count and a concomitant AIDS-
defining condition [4]. Unfortunately, although current guidelines recommend the ‘test and treat’
strategy [9], still late presentation represents a major clinical problem in HIV infection. Indeed, some BSI
etiologies such as Non-typhoidal Salmonella, Mycobacteria, and Cryptococci represent AIDS-defining
conditions and their incidence is strictly linked to late presentation.
Finally, many PLWH become older in the post cART era, with an increase in comorbidities typically
seen in the elderly, such as cardiovascular disease, hypertension, diabetes, chronic kidney disease,
and non-AIDS defining cancers.
In this scenario, we expect to observe an increased risk of hospitalization and exposure to
nosocomial infections in ageing HIV-infected populations, similar to that observed in HIV-negative
patients.
Regarding nosocomial infections, in recent years the prevalence of multidrug-resistant (MDR)
bacteria isolated from clinical samples continues to increase globally and Italy is one of the European
countries with the highest incidence of MDR [10–12].
The objective of this analysis was to describe BSI epidemiology in PLWH in a single center but
across a long period of time in the post cART era, focusing on antibiotic resistance data.
2. Materials and Methods
We performed a retrospective single-center observational study including all positive blood isolates
in HIV-infected patients older than 18 years and admitted to Azienda Ospedaliero-Universitaria of
Modena, Italy, from 1 January 2004 to 31 December 2017. Azienda Ospedaliero-Universitaria of
Modena is a 1100-bed tertiary teaching hospital, with an average of 46,000 admissions per year.
The study was approved by the local ethical committee (protocol number 15592, 9th, March 2016).
Informed consent was avoided according to Privacy Guaranteeing injunction nr. 85, 1st, March 2012,
art. 4.2.
Patient and microbiology data were collected from computerized a clinical database.
BSI diagnosis criteria were as follows: blood cultures positive for pathogen bacteria; CoNS,
Corynebacterium spp. and Propionibacterium spp. were regarded as contaminants, unless isolated from
two or more separate blood culture sets.
Repeated positive blood cultures for the same organism in the 14 days after the first episode
were excluded.
Hospital-acquired BSI was defined as a positive blood culture obtained on day 3 or later from
hospital admission [13].
Polymicrobial BSI was defined as isolation of more than one bacterial species from the same
blood cultures.
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Bacterial resistance tests were interpreted in accordance with CLSI criteria until 2009 and with
EUCAST break points from 2010. MDR, extensively drug-resistant (XDR) and pandrug-resistant
bacteria were defined according to ECDC consensus 2012 [14].
Virological failure was defined as an HIV-RNA > 200 copies/mL.
We evaluated the following patient characteristics: age, gender, CD4, CD8, CD4/CD8 ratio,
HIV-RNA, and cART.
Mean (SD) or median (IQR) were reported for continuous normally or non-normally distributed
variables and compared between groups using appropriate parametric and non-parametric tests;
categorical variables were described using frequencies and percentages and compared between groups
using the chi-square test.
Univariable and multivariable Generalised Estimating Equation (GEE) models using binomial
distribution family were fitted to evaluate the association between detection of MDR and the mortality
risk. Patients with Candida BSI were excluded from the GEE analysis because Gram classification was
not possible leading to missing data for this variable.
Statistical significance was defined on the basis of a p-value < 0.05. All statistical analyses were
performed by using STATA 13.1 for Windows (StataCorp, College Station, TX, USA).
3. Results
A total of 263 episodes, corresponding to 299 isolates and obtained from 164 patients, from
1 January 2004 to 31 December 2017 were retrospectively analyzed. Ninety (34%) patients had more
than one episode.
Community-acquired BSI represented 126 (48%) cases, while 137 (52%) were hospital-acquired.
Twenty-four (9%) were polymicrobial. Of the 263 episodes, 218 (82.8%) were collected in the internal
medicine wards, 22 (8.4%) in ICU, and 23 (8.8%) in surgical wards; 72 (27.4%) BSI originated from
central indwelling catheters (CVC) (4/9 in ICU, 40%).
Patient characteristics at BSI diagnosis, stratified by detection of antibiotic resistance, are shown
in Table 1.
Concerning HIV immune-virologic status, data were available for 172 episodes only. The majority
of patients were on effective cART (65.3%). Nevertheless, 34.7% of patients with BSI had a virological
failure, in particular 25% and 13% of patients presented HIV-RNA above 10,000 copies/mL and
100,000 copies/mL, respectively. Moreover, median CD4 count at the moment of the episode was low
(207 CD4/µL).
According to patient history and clinical files, patients presented a previous cART initiation in
205 episodes (88.4%, data available for a total of 232 episodes). Twenty-one patients, for a total of
27 episodes (11.6%), had never been prescribed antiretroviral treatment before BSI.
A total of 83 patients (48%) died, with a median survival time of 28 (IQR 6-274) days after the last
episode of bacteremia. It is noteworthy that 16 (19.3%) out of 83 patients died more than one year after
the last episode. Thirty-day mortality rate after the last episode was 24.2% while 90-day mortality rate
was 32.4%.
In particular, mortality rates for MDR isolates were 33.3% (22 patients) and 46.9% (31 patients)
at 30 and 90-days after last episode of bacteremia (both p-value < 0.05), respectively. No statistical
difference was found in median time to death after the last episode of bacteremia according to the
presence of specific MDR isolates.
Crude mortality rate for BSI was significantly higher for MDR isolates as compared to non-MDR
isolates (44.7% versus 24.3%, respectively).
Figures 1 and 2 show the distribution of BSI isolates in the entire hospital and in the different
hospital wards, respectively.
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Table 1. Patient characteristics at bloodstream infection diagnosis.
Patient Characteristics Total (263Obs)
Non MDR
Isolate (169 Obs)
MDR Isolate
(94 Obs)
p
Value
Age, median (IQR) 46 (40–52) 46 (41–52) 45 (40–52) 0.625
Male sex, n (%) 175 (66.5) 114 (67) 61 (65) 0.673
Year of event, n (%)
0.188
Before 2008 105 (40) 62 (36.7) 43 (45.7)
2009–2013 94 (35.7) 67 (39.6) 27 (28.7)
After 2014 64 (24.3) 40 (23.7) 24 (25.5)
Hospital acquired, n (%) 137 (52) 71 (42) 66 (70) <0.001
Years of HIV *, median (IQR) 14 (7–22) 15 (8–23) 11 (4–19) 0.021
Years of cART **, median (IQR) 5 (0–10) 5 (0–10) 5 (0–9) 0.944
CD4/CD8 ratio ***, median (IQR) 0.38 (0.13–0.64) 0.41 (0.14–0.66) 0.24 (0.10–0.60) 0.133
CD4 count ***, cell/µL, median (IQR) 207 (73–385) 216 (84–396) 186 (45–344) 0.356
CD4 count < 200/µL at event ***, n (%) 83 (47.4) 52 (45) 31 (52) 0.417
HIV RNA > 100.000 copies/mL at event ***, n (%) 23 (13.3) 12 (10.8) 11 (17.7) 0.198
HIV RNA > 10.000 copies/mL at event ***, n (%) 44 (25.4) 28 (25.2) 16 (25.8) 0.933
HIV RNA < 200 copies/mL at event ***, n (%) 113 (65.3) 75 (67) 38 (61) 0.406
Type of isolate, n (%)
0.061
Gram negative 119 (45.2) 82 (48.5) 37 (49.4)
Gram positive 139 (52.8) 82 (48.5) 57 (60.6)
Fungi 5 (2) 5 (3) 0 (0)
Death, n (%) 83 (31.6) 41 (24.3) 42 (44.7) <0.001
Gram negative 39 (32.8) 20 (24.4) 19 (51.4) 0.004
Gram positive 43 (30.9) 20 (24.4) 23 (40.4) 0.045
Fungi 1 (20) 1 (20) 0 (0) -
Polymicrobial, n (%) 24 (9.1) 15 (8.9) 9 (9.6) 0.854
Central venous associated bacteremia, n (%) 72 (27.4) 34 (20.1) 38 (40.4) <0.001
Gram negative 26 (36.1) 14 (41.2) 12 (31.6) 0.183
Gram positive 44 (61.1) 18 (52.9) 26 (68.4)
Fungi 2 (2.8) 2 (5.9) 0 (0)
ICU 9 (40.9) 5 (14.7) 4 (10.5)
0.849Surgery 6 (26.1) 3 (8.8) 3 (7.9)
Medicine 57 (26.2) 26 (76.5) 31 (81.6)
n: number; IQR: interquartile range; cART: combination antiretroviral treatment; HIV: human immunodeficiency
virus; VL: viral load; MDR: multidrug resistant; ESBL: extended-spectrum beta-lactamase; CRKP: carbapenem-
resistant K. pneumoniae; MRSA: methicillin-resistant S. aureus. * data available for 244 episodes only; ** data available
for 229 episodes only; *** data available for 173 episodes only.
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In the entire PLWH population, Enterobacteriaceae were the prevalent microorganisms (88, 29.8%),
followed by ConS (63, 21.4%), and S. aureus (38, 12.7%); non-fermenting Gram-negative bacteria were
37 (12.4%), Streptococci were 24 (8%) and Enterococci 22 (7.4%). Among Streptococci, S. pneumoniae
was the most frequent pathogen (11, 45.8%), followed by S. viridans group (5, 20.8%). Among
Enterobacteriace e, E. coli was th most frequent pathogen (49, 55.7%), followed by K. pneumoniae
(19, 21.6%) and E. cloac e (8, 9.1%).
A ong non-fermenting Gr m-negative organisms, the majority was P. aeruginosa (21, 56.8%),
followed by A. baumannii (4, 10.8%). E. faecalis was the most frequent organism among Enterococci
(11, 50%); E. faecium were 10 (45.5%). Among Staphylococcal bacteremia, CoNS were the most frequently
isolated (63, 62.4%) S. aureus was isolated in 38 cases (37.6%). CoNS accounted for 36% of CVC-related
BSIs (vs. peripheral lines p < 0.001). Staphylococcal isolates were resistant to methicillin in 63.4% of
cases. Candida spp. were 7 (2.3%).
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Among community-acquired BSIs, Gram negative were the most frequent pathogens, while
among nosocomial-acquired BSIs, Gram positive were the most prevalent (p = 0.001). No candidemia
was observed among community-onset BSIs. Regarding the different wards, Gram-positive isolates
were more frequent in the ICU and in medical wards, while Gram-negative isolates were prevalent in
surgical wards (p = 0.031). This higher prevalence of Gram-positive isolates in ICU could be related to
the enrichment of BSI from central indwelling lines.
Fifty-nine patients (34.1%) presented at least one bacteremia due to a MDR/XDR bacterium,
accounting for a total of 96 BSIs. In particular, 11 out of 38 (28.9%) S. aureus were methicillin-resistant
(MRSA). Extended spectrum beta-lactamases (ESBL) were present in 21 out of 88 Enterobacteriaceae
(23.9%); in particular, in 7 out of 49 (14.3%) E. coli and 9 out of 19 (47%) K. pneumoniae. Five out of 19
(26.3%) K. pneumoniae were carbapenemase-resistant (CRKP) and 6 out of 29 (20.7%) P. aeruginosa were
resistant to carbapenems, while 1 out of 22 Enterococci was resistant to vancomycin (4.6%).
Figure 3 shows the proportion of MDR/XDR isolates by calendar period of observation.
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Table 2. Univariable GEE model for factors associated with mortality.
Variables Total Population (258 Obs) Gram Negative (119 Obs) Gram Positive (139 Obs)
OR Std. Err. p Value 95% CI OR Std. Err. p Value 95% CI IRR Std. Err. p Value 95% CI
Age 1.04 0.02 0.009 1.01–1.07 1.08 0.03 0.004 1.02–1.14 1.02 0.01 0.249 0.99–1.06
Male sex 1.15 0.36 0.639 0.63–2.11 0.56 0.24 0.187 0.24–1.32 2.29 1.03 0.066 0.95–5.55
Years of c-ART 1.12 0.03 0.001 1.06–1.19 1.10 0.04 0.006 1.03–1.18 1.13 0.05 0.004 1.04–1.24
Years of HIV 1.02 0.16 0.331 0.98–1.05 1.03 0.02 0.176 0.99–1.08 1.00 0.02 0.872 0.95–1.04
CD4 count < 200 at event 0.67 0.23 0.255 0.34–1.33 1.09 0.55 0.859 0.41–2.94 0.39 0.19 0.050 0.16–1.00
HIV-RNA < 200 copies/mL at event 0.96 0.34 0.912 0.48–1.85 1.04 0.54 0.932 0.38–2.89 0.91 0.43 0.844 0.36–2.29
HIV-RNA > 100.000 copies/mL at event 0.64 0.35 0.410 0.22–1.83 0.43 0.36 0.317 0.08–2.25 0.73 0.52 0.657 0.18–2.93
HIV-RNA > 10.000 copies/mL at event 0.78 0.31 0.538 0.36–1.70 0.50 0.32 0.278 0.14–1.74 1.00 0.50 0.997 0.37–2.68
Hospital ward
ICU Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref
Surgery 0.32 0.20 0.075 0.09–1.12 1.04 0.13 0.072 0.01–1.22 0.16 0.19 0.118 0.02–1.58
Medicines 0.44 0.20 0.078 0.18–1.09 1.09 0.12 0.048 0.01–1.00 0.56 0.31 0.295 0.19–1.65
CVC-associated bacteremia 1.16 0.32 0.582 0.68–2.00 0.94 0.41 0.892 0.40–2.22 1.28 0.49 0.521 0.60–2.72
MDR isolate 2.46 0.65 0.001 1.46–4.13 3.37 1.41 0.004 1.48–7.65 2.12 0.78 0.041 1.03–4.34
ESBL isolate 1.83 0.63 0.077 0.94–3.59 1.57 0.61 0.249 0.73–3.37 - - - -
CRKP isolate 5.22 2.99 0.004 1.70–16.08 4.02 2.18 0.010 1.39–11.65 - - - -
MRSA isolate 3.48 2.22 0.051 1.00–12.15 - - - - 3.66 2.18 0.061 0.94–12.01
Obs: observations; OR: odd ratio; CI: confidence interval; c-ART: combination antiretroviral treatment; HIV: human immunodeficiency virus; VL: viral load; ICU: intensive care unit; CVC:
central venous catheter; MDR: multidrug resistant; ESBL: extended-spectrum beta-lactamase; CRKP: carbapenem-resistant K. pneumoniae; MRSA: methicillin-resistant S. aureus; GEE:
Generalised Estimating Equation
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Table 3. A: Multivariable GEE models for factors associated with mortality in the entire population; B: CRKP isolate subanalysis; C: MRSA isolate subanalysis.
A Unadjusted (258 Obs) Adjusted for Age (258 Obs) Adjusted for Age, Ward and CD4 Count * (172 Obs)
OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
MDR isolate 2.49 1.49–4.17 0.001 2.55 1.50–4.34 0.001 2.22 1.12–4.41 0.023
Age 1.04 1.01–1.07 0.009 1.04 1.00–1.07 0.046
B Unadjusted (258 Obs) Adjusted for Age (258 Obs) Adjusted for Age, Ward and CD4 Count * (172 Obs)
OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
CRKP isolate 5.22 1.70–16.08 0.004 4.45 1.39–14.22 0.012 1.84 0.46–7.39 0.388
Age 1.03 1.00–1.06 0.035 1.03 1.00–1.07 0.074
C Unadjusted (258 Obs) Adjusted for Age (258 Obs) Adjusted for Age, Ward and CD4 Count * (172 Obs)
OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
CRKP isolate 5.22 1.70–16.08 0.004 4.45 1.39–14.22 0.012 1.84 0.46–7.39 0.388
Age 1.03 1.00–1.06 0.035 1.03 1.00–1.07 0.074
(A) * Model adjusted for hospital ward and CD4 count < 200 cells/mcl at event (p-value > 0.05). Obs: observations; OR: odd ratio; CI: confidence interval; MDR: multidrug resistant;
(B) * model adjusted for hospital ward and CD4 count < 200 cells/mcl at event (p-value > 0.05). Obs: observations; OR: odd ratio; CI: confidence interval; MDR: multidrug resistant; CRKP:
carbapenem-resistant K.pneumoniae; (C) * model adjusted for hospital ward and CD4 count < 200 cells/mcl at event (p-value > 0.05). Obs: observations; OR: odd ratio; CI: confidence
interval; MRSA: methicillin-resistant S. aureus; GEE: Generalised Estimating Equation.
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Of note, BSI due to MDR organisms was associated with a twofold higher risk of death after
adjustment for age even if this correlation was not confirmed after further adjustment for CD4 < 200/µL.
As shown in the table, this result was confirmed in BSI due to CRKP and in BSI due to MRSA (although
results were more compatible with the null hypothesis of no difference).
HIV-associated variables did not associate with the mortality outcome in any of the analyses.
4. Discussion
To our knowledge this is the first study that describes BSI epidemiology in PLWH in the setting
of high MDR prevalence. Obviously, epidemiology and antibiotic resistance profile can vary widely
among different hospitals so it is very important to describe patterns of BSI in patients seen for care at
our institution in order to prescribe empirical antibiotic treatment.
In our study, Enterobacteriaceae (in particular E. coli) were the most frequent organisms involved
in BSI (29.8%) and this is in line with data obtained from the general population of the same region
(RER). Several studies showed a higher prevalence of Gram-positive bacteria in nosocomial BSI in
PLWH, with a proportion of Gram negative ranging from 20% to 31% [6,8,15]. Indeed, among patients
with hospital-onset BSI and patients admitted to the ICU, Gram-positive bacteria, particularly CoNS,
are the most prevalent pathogens. This finding could be explained by the higher prevalence of BSI
from central indwelling lines in this setting.
Concerning the resistance pattern, the proportion of detected MDR isolates did not differ
significantly over the years. Only the proportion of ESBL Enterobacteriaceae increased significantly
in the period 2014–2017. Comparing our resistance pattern to that in the RER [16] we can observe a
similar proportion of MRSA, a lower proportion of CRKP, and a slightly higher proportion of ESBL.
Actually, our data show that the BSI epidemiology in PLWH does not differ much from that of the
general population.
Regarding MRSA bacteremia, in our population of PLWH the percentage was 28.9%.
This prevalence is lower than expected as MRSA is usually considered more frequent in PLWH
than in the general population. Indeed, a recent study of Furuno et al. observed 66% of MRSA among
S. aureus bacteremia and studies suggested PLWH to be at increased risk of community-acquired
MRSA because of overlapping community networks as well as the high prevalence of intravenous
drug use [17].
Concerning HIV-related viro-immunological conditions, PLWH included in our study had a poor
status with a median of 207 CD4 cells/µL and a detectable HIV-viral load (VL) in 34.7% indicating
not only late presentation, but also, among those on cART treatment, either virological failure or
low adherence. Indeed, the study population has a worse immune-virological situation compared
to the average PLWH followed in the cART era in our clinic as typically more than 90% of patients
on cART have an undetectable HIV-VL [18]. This finding, although cross-sectional, is very relevant
and suggests that PLWH with poor adherence or a recent AIDS diagnosis are at increased risk of BSI.
Studies evaluating the role of CD4 count as risk factor for BSI in PLWH showed conflicting results.
On one hand, two studies described low CD4 counts in all hospitalized HIV patients, but they found no
significant difference in patients with and without BSI [15,19]. On the other hand, other three studies
described a significant increased incidence of bacterial BSI in HIV-infected patients with lower CD4
counts compared to those with a higher CD4 counts [20–22].
Despite the increased risk of BSI, HIV viro-immunological status was not associated with mortality
risk in our analysis, suggesting that they may play less of a role in the setting of people with BSI. Indeed,
CRKP bacteremia was a risk factor for mortality, while MRSA showed only a trend for an association.
In line with our findings, Furuno et al. showed a major role of MRSA bacteremia compared to HIV
viro-immunological status on mortality.
In our study the 30-and the 90-day mortality rates were similar to what has been described in both
PLWH and HIV-negative patients [6,23–26]. Mortality for BSI due to MDR isolates was significantly
higher than that observed in people without MDR (44.7% versus 24.3%, respectively).
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Our study has some limitations: first of all, it is a retrospective study, thus unmeasured confounding
factors cannot be ruled out. Indeed, some key potential confounders such as viro-immunological
characteristics, the prevalence of intravenous drug users, and antibiotic treatment were missing.
A correct inference also relies on a correct specification of the model and inclusion of all the important
measured confounding factors.
Nevertheless, we think that this study has some strengths: it is the first study conducted in an
MDR organisms endemic country and the observation period was very long period of time (13 years).
In conclusion, BSI in PLWH is still a major problem in the cART era and appears to be related to a
poor viro-immunological status. This underlines the importance of an early HIV diagnosis and a good
retention in care in order to strengthen a good adherence to cART. Importantly, now National and
International Guidelines [27,28] recommend in PLWH vaccinations against invasive bacterial diseases,
such as S. pneumoniae or H. influenzae so BSI incidence might decrease in the future as a consequence of
this intervention.
Finally, the implementation of antimicrobial stewardship programs and infection control strategies
remains key to reduce MDR BSI and protect frail populations from MDR infections.
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